Ascentage Pharma Group International ADR (AAPG)

Overview

Ascentage Pharma Group International stands as a clinical-stage biotech entity heavily invested in the development of novel therapies aimed at combating cancers, chronic hepatitis B virus (HBV), and diseases linked with aging. Operating across the United States and Mainland China, the company dedicates its expertise to crafting solutions that address some of the most challenging medical conditions today. Founded in the year 2009 and headquartered in Suzhou, China, Ascentage Pharma melds its deep-rooted scientific endeavors with strategic collaborations spanning globally recognized pharmaceutical firms, biotechnology leaders, and academic institutions. This broad network not only amplifies its research and development capabilities but also enriches its portfolio with innovative and potentially life-altering medical solutions.

Products and Services

• HQP1351:

  A forefront product, HQP1351 stands as a BCR-ABL inhibitor specifically targeting mutations within the BCR-ABL gene, including those resistant forms manifested in the T315I mutation. This precision-focused therapy is designed to combat certain types of leukemia by blocking the protein that promotes the growth of cancer cells.

• APG-2575:

  An orally administered Bcl-2 selective inhibitor, APG-2575 targets a protein known to prevent cancer cells from undergoing apoptosis, thereby proposing a novel treatment avenue for hematologic malignancies and solid tumors alike.

• APG-115:

  Serving as an oral small molecule inhibitor, APG-115 disrupts the MDM2-p53 protein-protein interaction, a pathway often exploited by various cancers to evade cell death. Its application spans solid tumors and hematological malignancies, offering a strategic approach to reactivating the body's natural tumor suppression process.

• APG-1387:

  APG-1387 is recognized for its role as a small molecule inhibitor targeting the inhibitors of apoptosis proteins (IAPs). This strategy not only holds potential in treating advanced solid tumors but also offers a promising therapeutic avenue for chronic HBV infection, aiming to restore the apoptotic ability of infected liver cells.

• APG-1252:

  This compound seeks to reinstate the apoptosis mechanism in cancer cells by selectively inhibiting Bcl-2 and Bcl-xL proteins. APG-1252's focus lies in addressing small cell lung cancer (SCLC), lymphoma, and other formidable solid tumors.

• APG-2449:

  An orally bioavailable solution, APG-2449 inhibits a trio of tyrosine kinases: FAK, ROS1, and ALK. By targeting these specific enzymes, the drug is positioned to impede the growth and spread of cancer cells, displaying a versatile approach to cancer therapy.

• APG-5918:

  APG-5918 represents a novel class of therapeutics as an orally available and selective EED inhibitor. Its mechanism focuses on modifying the epigenetic regulation of gene expression, a promising tactic in the fight against various cancers.

• APG-265:

  Targeting the MDM2 protein for degradation, APG-265 introduces a novel approach to cancer treatment by leveraging the body's natural system for regulating protein levels, thereby reinstating the p53 pathways to combat tumor growth.

• UBX1967/1325:

  While specific details are not provided, the inclusion of UBX1967/1325 in Ascentage Pharma's portfolio signifies its ongoing commitment to expanding its arsenal against diseases through cutting-edge medical research and development.

In addition to its product pipeline, Ascentage Pharma engages in venture capital investment and rental services, contributing to its diversified approach in advancing healthcare innovations and therapeutic discoveries.